Prof. MUDr. Sylvie Opatrná, Ph.D. †
I. interní klinika LF UK Praha a FN Plzeň
Prof. MUDr. Sylvie Opatrná, Ph.D. † je autorem těchto článků v časopise Postgraduální nefrologie:
Soohoo M, Moradi H, Obi Y, et al. Statin Therapy Before Transition to End‑Stage Renal Disease With Posttransition Outcomes. J Am Heart Assoc 2019;8:e011869.
Esgalhado M, Kemp JA, Azevedo R, et al. Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial. Food Funct 2018;9:6508–6516.
Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of Erythropoietin‑Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.
J Am Soc Nephrol 2019;30:1037–1048.
Nataatmadja MS, Johnson DW, Pascoe EM, et al.;
balANZ Trial Investigators. Associations between peritoneal glucose exposure, glucose degradation product exposure, and peritoneal membrane transport characteristics in peritoneal dialysis patients: secondary analysis of the balANZ trial.Perit Dial Int 2018;38:349–355.
Chaudry MS, Carlson N, Gislason GH, et al.
Risk of Infective Endocarditis in Patients with End Stage Renal Disease. Clin J Am Soc Nephrol 2017;12:1814–1822.
Leung CW, Quinn RR, Ravani P, et al.
Karaboyas A, Zee J, Brunelli SM, et al.
Kalim S, Wald R, Yan AT, et al.
Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles.
Clin J Am Soc Nephrol 2018;13:436-444.
Zavvos V, Buxton AT, Evans C, et al.
Kawase Y, Taniguchi T, Morimoto T, et al.
Severe Aortic Stenosis in Dialysis Patients. J Am Heart Assoc 2017;6. pii: e004961. doi: 10.1161/JAHA.116.004961.
Nazzal L, Roberts J, Singh P, et al.
Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut‑derived uremic solutes, indoxyl
sulfate and p‑cresyl sulfate, in end‑stage renal disease. Nefrol Dial Transplant 2017 Mar 31. doi: 10.1093/ndt/gfx029.
Buchanan C, Mohammed A, Cox E, et al.
Intradialytic cardiac magnetic resonance imaging to assess cardiovascular responses in a short‑term trial of
hemodiafiltration and hemodialysis. J Am Soc Nephrol 2017;28:1269–1277.
Redahan L, Davenport A.
Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients. J Nephrol
2016;29:427–434.
Chien CC, Han MM, Ciu YH, et al.
Epidemiology of cancer in end‑stage renal disease dialysis patients: a national cohort study in Taiwan.
J Cancer 2017;8:9–18.
Wang IK, Lu CY, Lin CL, et al. Comparison of the risk of de novo cardiovascular disease between hemodialysis and peritoneal dialysis in patients with end‑stage renal disease. Int J Cardiol 2016;218:219–224.
Craenenbroeck AHV, Craenenbroeck EMV, Ackeren KV, et al.
Impaired vascular function contributes to exercise intolerance in chronic kidney disease. Nefrol Dial Transplant 2016;31:2064–2072.
Hassan K, Kristal B, Hassan F, Abo Saleh S, Michelis R.: The impact of oxidized serum albumin on the oncotic pressure and hydration status of peritoneal dialysis patients. Ther
Clin Risk Manag 2016;12:463–469.
Lambie MR, Chess J, Summers AM, Williams PF, Topley N, Davies SJ; GLOBAL Fluid Study Investigators.
Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study. Nephrol Dial Transplant 2016;31:480–486.
Chang TI, Kang EW, Kim HW, et al. Low serum bicarbonate predicts residual renal function loss in peritoneal dialysis patients. Medicine 2015;94:e1276.
Gillespie BW, Morgenstern H, Hedgeman E, et al. Nephrology care prior to end‑stage renal disease and outcomes among new ESRD patients in the USA. Clin Kidney J 2015;8:772–780.
Sautenet B, Caille A, Giraudeau B, et al. Deficits in information transfer between hospital‑based and primary‑care physicians, the case of kidney disease: a cross‑sectional study. J Nephrol 2015;28:563–570.
Han SS, Park JY, Kang S, et al. Dialysis modality and mortality in the elderly: a meta‑analysis. Clin J Am Soc Nephrol 2015;10:983–993.
Chang TI, Nam JY, Shin SK, Kang EW. Low triiodothyronine syndrome and long‑term cardiovascular outcome in incident peritoneal dialysis patients. Clin J Am Soc Nephrol 2015;10:975–982.
Užitečnost diagnostického testování při vstupním vyšetření nemocných s chronickým onemocněním ledvin
Mendu ML, Lundquist A, Aizer AA, et al. The usefulness of diagnostic testing in the initial evaluation of chronic kidney disease. JAMA Intern Med 2015;175:853–856.
Barretti P, Doles JV, Pinotti DG, El Dib RP. Evidence‑based medicine: An update on treatments for peritoneal dialysis‑related peritonitis. World J Nephrol 2015;4:287–294.
Tsai YH, Chiu YW, Tsai JC, et al., Association of fluid overload with cardiovascular morbidity and all‑cause mortality in stages 4 and 5 CKD. Clin J Am Soc Nephrol 2015;10:39–46.
Dimitriadis C, Sekercioglu N, Pipili C, et al. Hyponatremia in peritoneal dialysis: epidemiology in a single center and correlation with clinical and biochemical parameters. Perit Dial Int 2014;34:260–270.
Pajek J, Hutchison AJ, Bhutani S, et al. Outcomes of peritoneal dialysis patients and switching to hemodialysis: a competing risks analysis. Perit Dial Int 2014;34:289–298.
Lan PG, Johnson DW, McDonald SP, et al. The association between peritoneal dialysis modality and peritonitis. Clin J Am Soc Nephrol 2014;9:1091–1097.
Al‑Hwiesh AK, Abdul‑Rahman IS, El‑Deen MA, et al. Metformin in peritoneal dialysis: a pilot experience. Perit Dial Int 2014;34:368–375.
Bertoli SV, Musetti C, Ciurlino D, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int 2014;34(1):64–70. doi: 10.3747/pdi.2012.00290
van Esch S, Krediet RT, Struijk DG. 32 years’ experience of peritoneal dialysis‑related peritonitis in a university hospital. Perit Dial Int 2014;34:162–170.
Weiner DE, Tighiouart H, Ladik V, Meyer KB, Zager PG, Johnson DS. Oral intradialytic nutritional supplement use and mortality in hemodialysis patients. Am J Kidney Dis 2014;63:276–285.
Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, Topley N. Dialysate interleukin‑6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. BMC Nephrology 2014;15:8
Li PKT, Culleton BF, Ariza A, et al. Randomized, controlled trial of glucose‑sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol 2013;24, doi:10.1681/ASN.2013080823
Rong Xu, Yaan Chen, Suping Luo, et al. Clinical characteristics and outcomes of peritoneal dialysis‑related peritonitis with different trends of chase in effluent white cell count: a longitudinal study. Perit Dial Int 2013;33:436–444.
Piraino B, Bernardini J, Brown E, et al. International Society for Peritoneal Dialysis Position Statement on reducing the risks of peritoneal dialysis‑related infections. Perit Dial Int 2011;31:614–630.
Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MWY, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 10.1681/ASN.2011121201.